PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.41%
Negative EBIT growth while Healthcare median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-25.41%
Negative operating income growth while Healthcare median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
610.74%
Net income growth of 610.74% while Healthcare median is zero. Walter Schloss might see potential if moderate gains can keep rising.
609.26%
EPS growth of 609.26% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
609.26%
Diluted EPS growth of 609.26% while Healthcare median is zero. Walter Schloss might see a slight edge that could improve over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
320.27%
OCF growth of 320.27% while Healthcare is zero. Walter Schloss might see a modest positive difference, which can compound over time.
320.27%
FCF growth of 320.27% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
419.54%
OCF/share CAGR of 419.54% while Healthcare median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
419.54%
OCF/share CAGR of 419.54% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
400.10%
3Y OCF/share growth of 400.10% while Healthcare median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
706.07%
Net income/share CAGR exceeding 1.5x Healthcare median of 28.82% over a decade. Joel Greenblatt might see a standout compounder of earnings.
706.07%
5Y net income/share CAGR > 1.5x Healthcare median of 27.05%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
315.93%
3Y net income/share CAGR > 1.5x Healthcare median of 20.67%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
-251.89%
Negative 10Y equity/share growth while Healthcare median is 0.00%. Seth Klarman would see a firm-specific weakness if peers still expand equity.
-251.89%
Negative 5Y equity/share growth while Healthcare median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-24.04%
Negative 3Y equity/share growth while Healthcare median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.74%
BV/share growth of 20.74% while Healthcare is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-14.44%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
30.71%
SG&A growth of 30.71% while Healthcare median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.